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Hepatocellular carcinoma (HCC) usually occurs in patients with underlying risk factors such as liver cirrhosis and chronic hepatitis
B. Although patients with Crohn’s disease (CD) are at an increased risk to develop malignancies such as colon cancer, the incidence
of HCC in this population is extremely rare. We report a case of 62-year-old male with long history of CD treated with azathioprine
(AZA) and aminosalicylic acid (ASA) who was incidentally diagnosed with HCC, for which left hepatectomy was done. Four
years later during routine follow-up, patient had another hepatic lesion and underwent resection of the mass. The mechanism of
occurrence of HCC in patient with CD is still controversial and may include immune mediated changes and medication related
complications. AZAwas reported in all case reports of CD that developedHCC.Through this report we hope to explore the complex
pathophysiological mechanisms contributing to the development of HCC in the Crohn’s disease patient population.
1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
neoplasmworldwide, with about 600,000 deaths annually [1].
HCC usually occurs in patients with underlying risk factor,
for example, liver cirrhosis or chronic hepatitis B [2]. Patients
with Crohn’s disease (CD) are at increased risk of developing
cancers, and colon cancer is considered the most important
cause of excess mortality among these patients [3]. The
incidence of HCC in the Crohn’s disease patient population
is extremely rare [4]. There are only few cases of HCC in
patients with CD reported in literature with only one case
reported of recurrent HCC [5]. We report a case of recurrent
HCC in a CD patient without underlying liver disease who
was treated with azathioprine (AZA) and aminosalicylic acid
(ASA).
2. Case Presentation
We present a case of a 62-year-old male with 42-year history
of small intestinal CD diagnosed at the age of 20, requiring
two small bowel resection surgeries during this course of
time. Our patient was solely on prednisone therapy for an
extended period of time and switched to AZA (150mg daily)
for the last 21 years with relatively well controlled symptoms.
During routine follow-up screening tests, he was incidentally
found to have left lobe liver mass and was diagnosed with
HCC for which he received left lobe hepatectomy at the age
of 58. The AZA dose was reduced to 50mg daily.
On subsequent follow-up, four years after the initial resec-
tion, he was found to have liver mass and was admitted to the
hospital for further evaluation. On presentation to hospital,
the patient appeared well without any evidence of jaundice
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Figure 1: Arterial phase showing 2.2 × 1.6 × 2.1 lesion in segment V.
or stigmata of chronic liver disease. Preoperative blood work
including liver profile and viral hepatitis markers was entirely
normal: AST 18U/L (<37U/L), ALT 16 (<60U/L), albumin
3.5 g/dL (3.5–5 g/dL), bilirubin 0.8mg/dL (0.3–1.2mg/dL),
and INR 1.0, alpha-fetoprotein 10.3 ng/mL (<6.1 ng/mL),
prothrombin time 13.3 seconds, and platelet count 210/𝜇L.
Triple phase contrast enhanced CT of abdomen showed
solitary mass in the segment 5 of the right lobe measuring 2.2
× 1.6 × 2.1 cm, with arterial enhancement and early wash out
in the venous phase, and no evidence of lymphadenopathy or
extrahepatic metastasis (Figures 1 and 2).
The decision toward surgical excision of the tumor was
made. Patient underwent laparoscopic resection of segment
5 with no postoperative complications. Microscopically, the
resected mass showed moderately differentiated hepatocel-
lular carcinoma without evidence of microvascular invasion
(Figure 3).
There was no postoperative adverse events and AZA was
discontinued and patient was kept on oral budesonide.
3. Discussion
Theoccurrence of HCC among patients with CD is extremely
rare, with only about 12 cases reported in the literature [5–16].
Most of the patients with CD who developed HCC received
AZA, with a few cases who did not receive AZA but were
eventually found to have underlying liver disease [9, 15].
The exact mechanism for the occurrence of HCC in
patients with CD without underlying liver disease is not well
established. Is it a pathophysiological outcome of Crohn’s dis-
ease itself? Or is it more related to the treatments of CD?The
answers to these scientific queries require further investiga-
tions.
AZA use is associated with increased risk of many malig-
nancies including squamous cell skin cancer in patients with
rheumatological diseases and lymphoma among IBDpatients
[17, 18]. However, there are no retrospective studies in med-
ical literature reporting any correlation between the use of
AZA and occurrence of HCC in patients with CD.
Figure 2: Hepatic lesion showing early wash out in venous phase.
There have been only two reported cases of hepatocellular
carcinoma in patients receiving azathioprine for clinical
conditions other than CD, one in patient with ulcerative
colitis and the other case in renal transplant patient [19, 20].
The relation between long term use of AZA and devel-
opment of HCC is still controversial, and the mechanism by
which AZA can predispose to HCC is thought to be due to
increase in the hepatic cells turnover. Arber et al. demon-
strated this effect on animals by injecting rats with AZA and
measuring the distance of labeled liver cells from the portal
space and found increase in the hepatocytes’ and littoral cells’
streaming velocities in the AZA treated rats compared to the
control group. This can possibly lead to aberrant cell growth
via abnormal mechanisms [21]. AZA can also precipitate to
cancers via decreasing the immunity against cancer cells and
increasing the susceptibility to oncogenic viruses [10].
Other possible mechanisms for the occurrence of HCC
in CD patients have been postulated; some endothelial-cell
adhesionmolecules and chemokines that are restricted to the
gut under normal condition become abnormally expressed in
the liver in IBD patients. This can lead to immune response
mediated by mucosal T cells, against these antigens and
subsequently hepatic damage [22].
Another reported pathophysiological mechanism is a
correlation between the gut microbiota in patients with CD
and occurrence ofHCC. Fox et al. showed that gutmicrobiota
can define the risk of HCC development in response to
environmental factors including carcinogenic chemicals and
hepatitis virus transgenes. Colonization of gut with harmful
bacteria is thought to alter bowel mucosal integrity facili-
tating the passage of harmful bacteria to portal circulation.
Also this change in gut microbiota can increase secretion
of cytokines acting on the liver and upregulating the tran-
scription of numerous cytokines and receptors that act as key
regulator of hepatic injury carcinogenesis [23, 24].
In conclusion, there appears to be complex interplay of
pathophysiological mechanisms in patients with CD, leading
to the development of HCC while on AZA therapy.
Gastroenterologist should be aware of this rare associa-
tion between using AZA in CD and development of HCC.
We hope that this intriguing area receives robust scientific
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Figure 3: Moderately differentiated HCC, hematoxylin and eosin: low power (a) and high power (b and c).
inquiry in order to establish a strong correlation and find out
if patients on AZA for CD should have screening for HCC.
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